The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in
tuberculosis drug discovery by breaking down barriers among competing labs and …

Exactly 125 years after the discovery of the etiological agent of tuberculosis (TB), the
disease remains as threatening as ever. The insufficient control measures in place today …

Published by AAAS (see figure, this page, top). However, the likelihood of the portfolio's
generating at least one successful compound by 2010 is less than 5%. As expected, when …

Tuberculosis (TB) is more prevalent in the world today than at any other time in human
history. Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse …

Historically, tuberculosis (TB) has fallen firmly in the group of 'neglected diseases'—
diseases in which pharmaceutical companies have been reluctant to invest due to a …

The “right of everyone to enjoy the benefits of scientific progress and its applications,” also
known as the right to science, is enshrined in the Universal Declaration of Human Rights …

“Since the time people have realised tuberculosis is preventable and since they have
learned how to avoid infection, mortality rates caused by tuberculosis have declined in …

The present decade has seen a reawakening of tuberculosis (TB) drug research and
development (R&D), spurred on by an urgent need to stem the tide of the disease globally …

Mycobacterium tuberculosis has a penetrance of its host population that would be the envy
of most human pathogens. About one-third of the human population would have a positive …

New Approaches to Filling the Gap in Tuberculosis Drug Discovery | PLOS Medicine Skip to
main content Advertisement PLOS Medicine Browse Current Issue Journal Archive Special …